麻豆传媒

Dapagliflozin (Farxiga) for patients with chronic kidney disease regardless of diabetes status, according to a post-hoc analysis of the DAPA-CKD trial. (Annals of Internal Medicine)

The , commonly used to treat conditions like type 2 diabetes and Parkinson's disease, improved blood pressure and arterial stiffness in teens with type 1 diabetes. (Hypertension)

Amgen announced it is tossing its hat into the obesity treatment ring, releasing -- a novel bispecific glucose-dependent insulinotropic polypeptide receptor antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist -- that achieved up to 14.5% body weight reduction at the highest dose after 12 weeks.

Data from a French health insurance system found that use of a GLP-1 receptor agonist for 1 to 3 years was linked with a 58% and a 78% higher risk for medullary thyroid cancer. (Diabetes Care)

Following years of setbacks, Lexicon Pharmaceutical is still trying to push its (Zynquista) through the FDA. (Endpoints News)

Semaglutide 2.4 mg (Wegovy) was more effective than liraglutide 3.0 mg (Saxenda) for weight loss in people with overweight or obesity (-12.47 kg vs -5.24 kg), but was also associated with more adverse events, according to a . (Clinical Epidemiology)

When diagnosing , should age-specific serum thyrotropin reference ranges be used? (Scientific Reports)

Kids with type 1 diabetes than kids without diabetes, though this didn't impair entry into higher education. (Diabetes Care)

Comment